EGFR Research Tools: Antibodies, Proteins & Stable Cell Lines

Epidermal Growth Factor Receptor (EGFR), also known as ERBB1 or HER1, is a single-pass transmembrane receptor tyrosine kinase and a central member of the ERBB receptor family. Its structure comprises an extracellular ligand-binding region with four subdomains, a transmembrane helix, an intracellular kinase domain and a regulatory C-terminal tail. Ligand binding promotes receptor dimerization and phosphorylation, activating major signaling networks such as RAS–RAF–MEK–ERK, PI3K–AKT–mTOR, PLCγ–PKC and JAK–STAT. These pathways regulate cell proliferation, survival, differentiation, migration and tissue repair. Activating mutations, gene amplification, receptor overexpression and other forms of pathway dysregulation are found across multiple solid tumors, making EGFR both an established biomarker and a major therapeutic target. Its broad expression and complex resistance biology also make assay design, epitope selection and model choice especially important during drug discovery.

EGFR drug development is mature but continues to evolve. Small-molecule tyrosine kinase inhibitors and extracellular-domain monoclonal antibodies have already reached regulatory approval in multiple oncology settings. Current research focuses on expanding mutation coverage, improving central nervous system penetration, reducing wild-type EGFR-related toxicity and overcoming acquired resistance. Mutation-selective and allosteric inhibitors range from approved products to late-stage clinical programs, while combination regimens with chemotherapy, immunotherapy or other targeted agents are being evaluated in mid- to late-stage trials. Antibody-drug conjugates and bispecific or multispecific antibodies are mainly in early- to mid-stage clinical development, aiming to improve payload delivery, increase tumor selectivity or block parallel resistance pathways. T-cell engagers, cell therapies, targeted degraders and other emerging modalities remain largely preclinical or early clinical. Across these approaches, biomarker-based patient selection, resistance profiling and longitudinal molecular monitoring are increasingly important for matching therapies to tumor biology.

DIMA BIOTECH provides a coordinated portfolio of EGFR research tools for discovery, screening and validation. The current range includes human, cynomolgus and mouse EGFR ECD proteins, multiple human fragments and tag formats, recombinant rabbit monoclonal antibodies, research-grade biosimilar reference antibodies, biotinylated and PE-conjugated antibody formats, and a Hu_EGFR K562 stable cell line. These products can support ELISA, flow cytometry, antigen–antibody binding analysis, assay optimization, species cross-reactivity studies, clone screening, reference benchmarking and cell-based target validation. They can also be used to establish positive controls, compare antibody formats and evaluate target recognition under different assay conditions. By combining matched proteins, antibodies, conjugates and stable cell models, researchers can build more efficient workflows from reagent qualification and epitope or affinity studies to early therapeutic antibody, bispecific and ADC development.